Release date- 13062016 - London- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its wholly-owned subsidiary West-Ward Pharmaceuticals, has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Letrozole Tablets 2.5mg.
Letrozole is a chemotherapy drug indicated for the treatment of breast cancer. According to IMS Health, total U.S. sales of Letrozole Tablets 2.5 mg were approximately $21 million for the 12 months ending April 2016.
Said Darwazah, Chairman and CEO of Hikma said, 'We are very pleased to have our first FDA approval from Hikma's dedicated oncology plant in Sahab, Jordan. We continue to leverage our strong global R&D teams and high-quality operational capabilities, to enhance our growing portfolio of more differentiated products.'
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: 'Injectables', 'Branded' and 'Generics', based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenue of $1,440 million and profit attributable to shareholders of $252 million.
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/
+44 7771 665277
Ben Atwell / Matthew Cole +44 (0)20 3727 1000
(c) 2016 Electronic News Publishing -, source ENP Newswire